<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2017.73033</article-id><article-id pub-id-type="publisher-id">ACM-21824</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20170300000_53589534.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  miR-3686调控PLK1表达相关机制的初步分析
  Analysis of the Mechanism of miR-3686 Regulates PLK1
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>靳</surname><given-names>红义</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邱</surname><given-names>新光</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>郑州大学第一附属医院，河南 郑州</addr-line></aff><aff id="aff2"><addr-line>中国人民解放军总医院，北京</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>28</day><month>07</month><year>2017</year></pub-date><volume>07</volume><issue>03</issue><fpage>202</fpage><lpage>207</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨miR-3686调控PLK1表达相关机制。方法：生物信息学软件分析预测miR-3686作用的靶基因。构建PLK1 3’UTR区的野生型和突变型载体，分别将其与miR-3686 mimics或者miR-3686 scramble共转染入HEK293T细胞中，运用双荧光素酶报告实验验证miR-3686的作用靶基因。构建无3’UTR区PLK1的表达载体，单独转入或与miR-3686 mimics共转染入PANC1细胞中，Western blot实验检测各组细胞PLK1蛋白的表达水平；restore transwell实验检测转染后各组细胞的侵袭能力，分析miR-3686靶向调控PLK1表达的作用机制。结果：无3’UTR区的PLK1的表达可以不受miR-3686的调控而发挥增强PANC1细胞侵袭能力的作用。结论：PLK1是miR-3686的靶基因。miR-3686通过作用于靶基因PLK1基因的3’UTR区来发挥其生物学效应。
    Objective: Analysis of the mechanism of miR-3686 regulates PLK1. Methods: Bioinformatic analysis predicted the target of miR-3686. The wild-type and mutant 3’UTR segments of PLK1 were constructed into pmirGLO, then cotransfected into HEK293T cell along with miR-3686 mimics or scramble. Luciferase reporter assays determined whether PLK1 is regulated by miR-3686. pcDNA3.1-PLK1 was constructed and cotransfected into PANC1 cell with miR-3686 mimics or scramble. Western blot was used to determine the PLK1 protein expression level. Restore transwell assay was used to determine the invasion of every group, to analyze the interaction mechanism between miR-3686 and PLK1. Results: The results of bioinformatic analysis and luciferase reporter assays indicated PLK1 is regulated by miR-3686. The restore experiments showed that PLK1 without 3’UTR of wasn’t regulated by miR-3686, and its function can offset the roles of miR-3686 on the biological behavior of the pancreas carcinoma cell line PANC1. Conclusion: miR-3686 had an inverse correlation with PLK1. In pancreas carcinoma cell line PANC1, upregulation of miR-3686 inversely regulated PLK1 expression by binding to PLK1 mRNA 3’UTR, which can suppress cell proliferation, migration and promote cell cycle block, cell apoptosis. 
  
 
</p></abstract><kwd-group><kwd>胰腺癌细胞，miR-3686，PLK1, Pancreas Cancer Cell</kwd><kwd> miR-3686</kwd><kwd> PLK1</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>miR-3686调控PLK1表达相关机制的初步分析<sup> </sup></title><p>靳红义<sup>1</sup>，邱新光<sup>2</sup></p><p><sup>1</sup>中国人民解放军总医院，北京</p><p><sup>2</sup>郑州大学第一附属医院，河南 郑州</p><p>收稿日期：2017年7月30日；录用日期：2017年8月21日；发布日期：2017年8月28日</p><disp-formula id="hanspub.21824-formula11"><graphic xlink:href="http://html.hanspub.org/file/11-1570352x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨miR-3686调控PLK1表达相关机制。方法：生物信息学软件分析预测miR-3686作用的靶基因。构建PLK1 3’UTR区的野生型和突变型载体，分别将其与miR-3686 mimics或者miR-3686 scramble共转染入HEK293T细胞中，运用双荧光素酶报告实验验证miR-3686的作用靶基因。构建无3’UTR区PLK1的表达载体，单独转入或与miR-3686 mimics共转染入PANC1细胞中，Western blot实验检测各组细胞PLK1蛋白的表达水平；restore transwell实验检测转染后各组细胞的侵袭能力，分析miR-3686靶向调控PLK1表达的作用机制。结果：无3’UTR区的PLK1的表达可以不受miR-3686的调控而发挥增强PANC1细胞侵袭能力的作用。结论：PLK1是miR-3686的靶基因。miR-3686通过作用于靶基因PLK1基因的3’UTR区来发挥其生物学效应。</p><p>关键词 :胰腺癌细胞，miR-3686，PLK1</p><disp-formula id="hanspub.21824-formula12"><graphic xlink:href="http://html.hanspub.org/file/11-1570352x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2017 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="http://image.hanspub.org:8080\Html/htmlimages\1-2890033x\e70a10f1-7c93-45ea-9603-062237856e4b.png" /><img src="http://image.hanspub.org:8080\Html\htmlimages\1-2890033x\e898c85e-ffc4-45c9-b817-14224a4d6960.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>胰腺癌是恶性程度极高的一种消化道肿瘤，其极易转移且转移速度极快，一旦发病，预后极差。流行病学调查显示，胰腺癌的死亡率位居美国恶性肿瘤死亡病因的第四位。根据中国肿瘤2011年登记年报的数据，位于我国恶性肿瘤发病率排名的第七名。胰腺癌早期不易诊断出来，因为其症状出现的极晚，所以胰腺癌的总体死亡率很高。有资料显示 [<xref ref-type="bibr" rid="hanspub.21824-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.21824-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.21824-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.21824-ref4">4</xref>] ，胰腺癌的5年生存率仅为5%~10%。胰腺癌的发生是一个多因素，多步骤的过程，但是具体机制尚不明确。本研究以miR-3686为基础，探讨miR-3686调控PLK1表达相关机制，为探索参与胰腺癌发生发展过程的miRNAs的调控机制提供实验基础。</p></sec><sec id="s4"><title>2. 实验材料</title><sec id="s4_1"><title>2.1. 细胞株</title><p>实验用胰腺癌细胞株PANC1和人胚肾细胞HEK293T均购自上海中科院细胞库。细胞在37℃，5% CO<sub>2</sub>培养箱中培养，确保各实验细胞在实验中均处于指数增长期。</p></sec><sec id="s4_2"><title>2.2. 细菌</title><p>TOP10和DH5α大肠杆菌购自于Invitrogen公司。</p></sec><sec id="s4_3"><title>2.3. 质粒</title><p>pmirGLO-Enhancer载体和pEGM-T载体均购于美国Promega公司，pcDNA3.1(+)载体购于Invitrogen公司。</p></sec></sec><sec id="s5"><title>3. 实验方法</title><p>运用TargetScan和miRanda软件分析预测miR-3686的靶基因。通过对二者结果的交集进行分析，预测PLK1是miR-3686的靶基因。然后进行双荧光素酶报告实验、Restore实验。</p>统计学分析<p>用SPSS 21.0统计软件对实验数据进行统计学分析，计量资料采用<inline-formula><inline-graphic xlink:href="http://html.hanspub.org/file/11-1570352x9_hanspub.png" xlink:type="simple"/></inline-formula>计数，设定α = 0.01为检验水准。</p></sec><sec id="s6"><title>4. 实验结果</title><sec id="s6_1"><title>4.1. miR-3686的靶基因生物信息学预测</title><p>通过TargetScan和miRanda软件是分析和预测，结果见图1。PLK1的3’UTR区包含miR-3686的互补区域。提示PLK1可能是miR-3686的靶基因。</p></sec><sec id="s6_2"><title>4.2. 双荧光素酶报告实验验证miR-3686的靶基因</title><sec id="s6_2_1"><title>4.2.1. 重组报告基因载体的构建</title><p>1) 目的片段扩增结果：取5 &#181;L PCR扩增出的PLK1野生型3’UTR片段全长(325 bp)，突变型上片段(255 bp)和下片段(103 bp)及采用overlap PCR扩增出的PLK1突变型3’UTR片段全长(325 bp)，进行琼脂糖凝胶电泳，结果见图2。片段大小均与预期长度一致。</p><p>2) 重组报告基因载体鉴定：</p><p>酶切鉴定结果：提取PmirGLO-PLK1质粒，用Sac I和Xho I进行双酶切鉴定，结果见图3。</p><p>图1. miR-3686靶基因预测</p><p>图2. PLK1野生型和突变型全长的PCR扩增产物</p><p>1：PLK1野生型全长，2：PLK1突变型下片段， 3：PLK1突变型上片段，4：PLK1突变型全长，M：Marker</p><p>图3. 重组载体双酶切后鉴定产物</p><p>1：PLK1野生型全长，2：PLK1突变型全长，M：Marker</p></sec><sec id="s6_2_2"><title>4.2.2. 双荧光素酶报告检测结果</title><p>采用双荧光素酶报告系统检测荧光素酶活性变化，结果见表1。共转染miR-3686 mimics和含有PLK1野生型3’UTR区组的细胞的荧光素酶活性相较于其他三组细胞呈明显下调状态(P &lt; 0.01)。共转染miR-3686 mimics和含有PLK1突变型3’UTR区的重组载体组，以及共转染有miR-3686 scramble和两种载体组的萤光素酶活性之间没有出现明显的差异(P &gt; 0.01)。提示miR-3685与PLK1 3’UTR区相互作用，使得miR-3686可负向调控PLK1的表达。</p></sec></sec><sec id="s6_3"><title>4.3. Restore实验</title>无3’UTR区pcDNA3.1-PLK1表达载体构建<p>PCR扩增无3’UTR区的PLK1，扩增产物凝胶电泳，结果见图4。用BamHI和EcoRI双酶切鉴定pcDNA3.1双粘载体与无3’UTR区PLK1片段重组的表达载体，电泳结果见图5。鉴定结果均与预期一致，提示无3’UTR区pcDNA3.1-PLK1重组表达载体构建成功。</p></sec></sec><sec id="s7"><title>5. 讨论</title><sec id="s7_1"><title>5.1. PLK家族成员的特点</title><p>PLK家族成员的特点在于它们具有经典的丝氨酸苏氨酸结合域，这一区域半数位于该分子的N末端和PBD的C末端，是PLK家族特异的属性。PLK1-3的PBDs都由PB1和PB2组成，具有相同的结构。人类PLK1的PBD调节PLK1的催化活性、定位和底物结合能力。这一区域组成一个结合袋以适应其他蛋白质丝氨酸或者苏氨酸残基磷酸化 [<xref ref-type="bibr" rid="hanspub.21824-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.21824-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.21824-ref6">6</xref>] 。PLK家族成员的PBDs磷酸化结合的最佳时机由定向肽筛查决定 [<xref ref-type="bibr" rid="hanspub.21824-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.21824-ref6">6</xref>] 。</p></sec><sec id="s7_2"><title>5.2. PLK1发挥作用的机制</title><p>PLK1通过PBD的定向活动进行空间调节。现有的比较有说服力的模型是PBD与一种磷酸化肽类物质结合模型，这种肽类物质由CDK1或者其他具有亲和力的蛋白激酶催化产生。此外，PLK1通过产生自身的PBD连接位点自我推进自身的定位 [<xref ref-type="bibr" rid="hanspub.21824-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.21824-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.21824-ref6">6</xref>] 。</p><p>图4. 无3’UTR区PLK1的PCR产物</p><p>图5. pcDNA3.1-PLK1重组载体双酶切鉴定产物</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Results of dual luciferase repor</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >荧光素酶活性相对值</th></tr></thead><tr><td align="center" valign="middle" >miR-3686和PLK1-WT共转染组</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.6188 &#177; 0.0552<sup>*</sup></td></tr><tr><td align="center" valign="middle" >scramble和PLK1-WT共转染组</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.0014 &#177; 0.4357</td></tr><tr><td align="center" valign="middle" >miR-3686和PLK1-MUT共转染组</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.2630 &#177; 0.4119</td></tr><tr><td align="center" valign="middle" >scramble和PLK1-MUT共转染组</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.1913 &#177; 0.3852</td></tr></tbody></table></table-wrap><p>表1. 各组细胞的荧光素酶活性</p><p>PBD与激酶结合域的结合抑制了PLK1的酶活性同时减弱了PBD和磷酸化肽类物质的联系 [<xref ref-type="bibr" rid="hanspub.21824-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.21824-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.21824-ref9">9</xref>] 。</p><p>生物信息学软件分析预测了PLK1的的3’UTR区包含miR-3686的结合位点，提示PLK1可能是miR-3686的作用靶基因。PLK1能够在肿瘤治疗中代表一种优秀的预示性标志物多是由于它参与整个细胞周期的多个步骤以及其对肿瘤细胞的特异性；PLK1的多种功能被引入生物学、医学、药学的研究中 [<xref ref-type="bibr" rid="hanspub.21824-ref10">10</xref>] 。</p><p>为了进一步验证软件分析预测结果，本研究进行了双荧光素酶报告实验和qRT-PCR。qRT-PCR结果显示PLK1在胰腺癌组织中的表达水平明显高于其对应的癌旁组织，并且PLK1的表达水平与胰腺癌患者的分化程度、TNM分期以及淋巴结的转移情况有密切关系。PANC1细胞的双荧光素酶报告实验的结果显示共转染miR-3686 mimics和野生型PLK1的3’UTR区重组载体时，其萤光素酶活性显著降低。而共转染miR-3686 mimics和突变型PLK1的3’UTR区的重组载体的细胞，以及转染miR-3686 scramble和重组报告载体的细胞的萤光素酶活性之间没有出现明显的差异。以上结果表明：miR-3686可以通过作用于PLK1的3’UTR区，从而负向调控其表达水平。</p><p>为了进一步研究miR-3686对PLK1的调控作用的机制，本研究进行了restore实验。在本实验中，我们构建了无3’UTR区的pcDNA3.1-PLK1表达载体。PLK1蛋白的Western blot实验结果显示表明，相对于Mock组，miR-3686组PLK1蛋白的表达水平显著降低，pcDNA3.1-PLK1组PLK1蛋白的表达水平显著升高。miR-3686 mimics和pcDNA3.1-PLK1共转染组PLK1蛋白的表达水平与pcDNA3.1-PLK1组PLK1蛋白的表达水平没有明显变化。细胞侵袭实验结果表明：相对于Mock组，miR-3686 mimics和pcDNA3.1-PLK1共转染组和pcDNA3.1-PLK1组细胞迁移通过基质胶的PANC1细胞数均显著升高。</p><p>综上结果表明，miR-3686通过作用于PLK1的3’UTR区负向调控PLK1的表达，从而抑制胰腺癌细胞的侵袭和转移能力。</p></sec></sec><sec id="s8"><title>文章引用</title><p>靳红义,邱新光. miR-3686调控PLK1表达相关机制的初步分析 Analysis of the Mechanism of miR-3686 Regulates PLK1[J]. 临床医学进展, 2017, 07(03): 202-207. http://dx.doi.org/10.12677/ACM.2017.73033</p></sec><sec id="s9"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.21824-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Xu, J., Shen, C., Wang, T., et al. (2013) Structural Basis for the Inhibition of Polo-Like Kinase 1. Nature Structural &amp; Molecular Biology, 20, 1047-1053. &lt;br&gt;https://doi.org/10.1038/nsmb.2623</mixed-citation></ref><ref id="hanspub.21824-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Kettenbach, A.N., Schweppe, D.K., Faherty, B.K., et al. (2011) Quantitative Phosphoproteomics Identifies Substrates and Functional Modules of Aurora and Polo-Like Kinase Activities in Mitotic Cells. Science Signaling, 4, rs5.  
&lt;br&gt;https://doi.org/10.1126/scisignal.2001497</mixed-citation></ref><ref id="hanspub.21824-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bai, Y., Li, J., Fang, B., et al. (2012) Phosphoproteomics Identifies Driver Tyrosine Kinases in Sarcoma Cell Lines and Tumors. Cancer Research, 72, 2501-2511. &lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-11-3015</mixed-citation></ref><ref id="hanspub.21824-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Bieging, K.T., Mello, S.S. and Attardi, L.D. (2014) Un-ravelling Mechanisms of p53-Mediated Tumour Suppression. Nature Reviews Cancer, 14, 359-370. &lt;br&gt;https://doi.org/10.1038/nrc3711</mixed-citation></ref><ref id="hanspub.21824-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Salvi, M., Trashi, E., Cozza, G., et al. (2012) Investigation on PLK2 and PLK3 Substrate Recognition. Biochimica et Biophysica Acta, 1824, 1366-1373.</mixed-citation></ref><ref id="hanspub.21824-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Bruinsma, W., Macurek, L., Freire, R., et al. (2014) Bora and Aurora-A Continue to Activate Plk1 in Mitosis. Journal of Cell Science, 127, 801-811. &lt;br&gt;https://doi.org/10.1242/jcs.137216</mixed-citation></ref><ref id="hanspub.21824-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Craig, S.N., Wyatt, M.D. and McInnes, C. (2014) Current Assessment of Polo-Like Kinases as Anti-Tumor Drug Targets. Expert Opinion on Drug Discovery, 9, 773-789. &lt;br&gt;https://doi.org/10.1517/17460441.2014.918100</mixed-citation></ref><ref id="hanspub.21824-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Gjertsen, B.T. and Schoffski, P. (2015) Discovery and Development of the Polo-Like Kinase Inhibitor Volasertib in Cancer Therapy. Leukemia, 29, 11-19. &lt;br&gt;https://doi.org/10.1038/leu.2014.222</mixed-citation></ref><ref id="hanspub.21824-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Cholewa, B.D., Liu, X. and Ahmad, N. (2013) The Role of Polo-Like Kinase 1 in Carcinogenesis: Cause or Consequence? Cancer Research, 73, 6848-6855. &lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-13-2197</mixed-citation></ref><ref id="hanspub.21824-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">McInnes, C. and Wyatt, M.D. (2011) PLK1 as an Oncology Target: Current Status and Future Potential. Drug Discovery Today, 16, 619-625.</mixed-citation></ref></ref-list></back></article>